Teva Pharmaceutical reported Q3 2024 revenues of $4.3 billion, up 13% year-over-year, driven by higher generic product sales across all segments and strong AUSTEDO growth. U.S. segment revenues increased 17% to $2.2 billion, with AUSTEDO revenues up 28% to $435 million. Generic products revenue rose 30% to $1.1 billion in the U.S.The company recorded an operating loss of $51 million, compared to operating income of $344 million in Q3 2023, mainly due to a $600 million goodwill impairment charge related to its API business and a $450 million provision for legal settlements, including a $350 million fine from the European Commission regarding COPAXONE antitrust investigation.Gross profit margin improved to 49.6% from 48.1% last year on favorable product mix. The company generated free cash flow of $922 million in Q3. Net debt decreased to $18.98 billion as of September 30, 2024. Teva maintained its full-year outlook and continues to execute on its "Pivot to Growth" strategy focused on innovative medicines and biosimilars while sustaining its generics business.

Teva Pharmaceutical reported Q3 2024 revenues of $4.3 billion, up 13% year-over-year, driven by higher generic product sales across all segments and strong AUSTEDO growth. U.S. segment revenues increased 17% to $2.2 billion, with AUSTEDO revenues up 28% to $435 million. Generic products revenue rose 30% to $1.1 billion in the U.S.The company recorded an operating loss of $51 million, compared to operating income of $344 million in Q3 2023, mainly due to a $600 million goodwill impairment charge related to its API business and a $450 million provision for legal settlements, including a $350 million fine from the European Commission regarding COPAXONE antitrust investigation.Gross profit margin improved to 49.6% from 48.1% last year on favorable product mix. The company generated free cash flow of $922 million in Q3. Net debt decreased to $18.98 billion as of September 30, 2024. Teva maintained its full-year outlook and continues to execute on its "Pivot to Growth" strategy focused on innovative medicines and biosimilars while sustaining its generics business.